ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500 ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received an average rating of “Hold” from the eighteen brokerages that are covering the stock, Marketbeat.com reports.One analyst ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the ...